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Background: Pleotropic effects of statins on inflammation are hypothesised to attenuate the severity of and
possibly prevent the occurrence of the host inflammatory response to pathogen and infection-related acute organ
failure. We conducted an international survey of intensive care physicians in Australia, New Zealand (ANZ) and
United Kingdom (UK). The aims of the survey were to assess the current prescribing practice patterns, attitudes
towards prescribing statin therapy in critically ill patients and opinions on the need for an interventional trial of
statin therapy in critically ill patients.
Methods: Survey questions were developed through an iterative process. An expert group reviewed the resulting
26 items for face and content validity and clarity. The questions were further refined following pilot testing by ICU
physicians from Australia, Canada and the UK. We used the online Smart SurveyTM software to administer the
survey.
Results: Of 239 respondents (62 from ANZ and 177 from UK) 58% worked in teaching hospitals; most (78.2%)
practised in ‘closed’ units with a mixed medical and surgical case mix (71.0%). The most frequently prescribed
statins were simvastatin (77.6%) in the UK and atorvastatin (66.1%) in ANZ. The main reasons cited to explain the
choice of statin were preadmission prescription and pharmacy availability. Most respondents reported never starting
statins to prevent (65.3%) or treat (89.1%) organ dysfunction. Only a minority (10%) disagreed with a statement that
the risks of major side effects of statins when prescribed in critically ill patients were low. The majority (84.5%) of
respondents strongly agreed that a clinical trial of statins for prevention is needed. More than half (56.5%) favoured
rates of organ failure as the primary outcome for such a trial, while a minority (40.6%) favoured mortality.
Conclusions: Despite differences in type of statins prescribed, critical care physicians in the UK and ANZ reported
similar prescription practices. Respondents from both communities agreed that a trial is needed to test whether
statins can prevent the onset of new organ failure in patients with sepsis.
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Host immune and inflammatory response to infection
manifests as sepsis syndromes [1]. Sepsis is common
and its incidence appears to be increasing[2,3],
accounting for 27% of United Kingdom (UK) and 12%
of Australia-New Zealand (ANZ) critical care admis-
sions [4]. Worryingly the reported case fatality rate
from sepsis syndromes remains high (25%-50%) [5].
The estimated annual cost of treating sepsis in the
United States was $16.7 billion [5], whilst the esti-
mated cost of managing a patient with sepsis in the
intensive care unit has been reported to vary between
$19,000 to $28,000 [6]. Furthermore, interventions such
as resuscitation of patient with sepsis further adds to the
management cost [7].
The biology of sepsis syndrome is characterised by un-
regulated systemic inflammation and immune dysfunc-
tion involving multiple pathways [8]. Numerous studies
have tested the efficacy and effectiveness of immune-
modulating agents; so far all have failed to show benefit.
One reason may be that modulating a single immune
target, embedded in a complex system with multiple re-
dundancy, is insufficient to effect a subsequent improve-
ment in morbidity or mortality[9]. Testing agents with
modulating effects at multiple points may therefore be a
more successful strategy [10-14] to prevent the onset of
acute organ failure.
Statins are 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors with an established
role in primary and secondary prevention of cardiovas-
cular events by lowering low-density lipoprotein choles-
terol [15]. Recent mechanistic reviews show statins
influence inflammatory pathways at multiple levels
through effects on cellular signalling pathways independ-
ent of lipid lowering ability [16,17]. In addition to the
potential role in treating critically ill patients with estab-
lished organ dysfunction like sepsis syndromes [14] and
acute lung injury [13], statins have also been proposed
as a potential intervention to prevent new organ dys-
function in sepsis [18].
HMGCoA reductase catalyses the rate limiting step in
the production of cholesterol by inhibiting the conver-
sion of HMG CoA to mevalonate. As a consequence of
this action, the intermediates of the mevalonate pathway
are also reduced. Under normal circumstances the
mevalonate pathway leads to the formation of isopre-
noids which regulate the lipid modification of proteins
necessary for interaction with cellular membranes which
drive inflammatory responses. Inhibition of isoprenoid
formation by statins therefore, has significant anti-
inflammatory effects. These have been demonstrated
in vitro and in vivo as well as in a human model of pul-
monary inflammation induced by inhaled endotoxin
[19]. Enzymes of the mevalonate pathways are also keyfor gram positive bacterial infection pathogenesis and
are considered potentially modifiable with statin therapy
[20]. Statins could potentially improve bacterial clear-
ance by neutrophils and macrophages via novel extracel-
lular traps linked to sterol pathway inhibition [21].
Antibacterial activity of compounds is often reported in
terms of minimum inhibitory concentrations (MIC).
However, the MICs required for antibacterial activity of
statins invitro is much higher (approximately 1000
times) than what is achieved during conventional dosing
for lipid homeostasis [22,23]. Therefore, the current
thinking is that the antibacterial bacterial effects of sta-
tins are minimal at conventional doses and they are
likely to be concentration independent, complex and as
yet not fully clarified [22,24].
The literature on statin and sepsis is predominantly
comprised of observational studies with inconsistent
results and characterized by methodological limitations
[25-27]. A recently published systematic review and
meta analysis identified a potential publication bias in
the existing literature on statin therapy and infections,
and suggested that such publication bias might explain
the inconsistent results from previous research [28].
These findings serve to highlight the need for well-
designed interventional trials of statins to clarify their
potential benefits in modulating the response to infec-
tions [29].
There is paucity of published evidence on the current
critical care practices of statin prescribing. We con-
ducted an international survey of critical care units in
the United Kingdom (UK) and Australia & New Zealand
(ANZ) to study current practice patterns of statin pre-
scription in the critical care setting and to obtain back-
ground information to help inform the design of an
interventional trial testing the hypothesis that statin
therapy can prevent new acute organ failure.
Methods
Study participants
We targeted critical care physicians in UK and Australia
identified using mailing lists maintained by The In-
tensive Care Society in the UK and The Australian
and New Zealand Intensive Care Society Clinical Trials
Group.
Survey development
Study investigators generated potential items for the sur-
vey by reviewing the literature on sepsis and statins and
by seeking expert opinions [16,30]. Item reduction was
achieved using an iterative process involving all 7 study
investigators, 5 other critical care physicians and 2 exter-
nal appraisers. The survey questionnaire was pilot tested
using a group of senior critical care physicians and
researchers from Canada, UK and ANZ (n = 15) to
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formats, and to assess its content, face validity and clar-
ity [31]. The final survey questionnaire consisted of 26
items arranged into 3 domains. The online Smart Sur-
veyTM software was used to format the questionnaire
prior to administration [32]. The research and ethics
committee at Guy’s and St Thomas’ Hospital NHS Foun-
dation Trust considered the study to pose minimal risk
and waived the need for formal ethical review.
Survey administration
Potential respondents were initially contacted by email.
The email included a cover letter explaining the purpose
of the survey and a link to the web-based Smart survey
tool. A follow up reminder was sent 4 weeks after the
initial mailing. No incentives were provided for respond-
ing to the survey.
Survey overview
The 3 survey domains were aimed at (1) understanding
the respondent demographics and the intensive care unit
characteristics including management policy, (2) deter-
mining the current practice patterns of statin therapy in
critical illness, and (3) gathering opinions on key design
issues for a proposed interventional trial of statin ther-
apy in early critical illness.
The intensive care units management policy was
defined using the following terms: a) ‘open’ refers to the
policy where the referring physician remains directly re-
sponsible for majority of day to day patient care; b)
‘closed’ refers to the policy where the referring physi-
cians hand over care to critical care physicians who are
responsible for majority of day to day patient care until
critical care discharge; and c) hybrid refers a combin-
ation of open and closed.
The current practice patterns of statin therapy were
evaluated using scenarios in two separate contexts: 1)
initiating new statin prescriptions (i.e. patients who are
statin-naive), and 2) continuing pre admission prescrip-
tions following admission to critical care. The likelihood
with which new statin prescriptions are initiated follow-
ing critical care admission in patients’ NOT previously
receiving statins was evaluated using the following 3
clinical scenarios: (1) a new cardiac indication during
critical care admission; (2) preventing organ dysfunction
in sepsis; and (3) treating organ dysfunction in severe
sepsis. The frequency with which pre admission statin
prescriptions are continued following critical care admis-
sions for patients who were previously receiving statins
was evaluated using the following 4 clinical scenarios:
(1) outpatient indication like hyperlipidaemia without a
new acute cardiac indication; (2) a new acute cardiac in-
dication during critical care admission (e.g. acute coron-
ary syndrome); (3) for preventing organ dysfunction insepsis; and (4) for treating organ dysfunction in severe
sepsis.
Statistical analysis
We report responses to survey questions overall and by
country (UK and ANZ). Institutional and ICU character-
istics are described using proportions. Likert format re-
sponse items were used to evaluate the reported statin
prescribing practice and opinions on trial design.
Reported practice and opinions evaluated using 5-point
Likert scales are graphically represented by grouping
responses at the tails (i.e. 1 and 2 grouped, 4 and 5
grouped). The grouping 1/2 refers to ‘frequently/always’
and grouping 4/5 refers to ‘infrequently/never’; the
remaining value 3 refers to ‘sometimes’ in the ‘Likert
Scale’ choices used to seek opinions. The Chi square test
(and Fisher exact test when number of observations in
any category was less than 5) was used to evaluate the




We received a total of 239 responses (177 from UK and
62 from ANZ). More respondents (overall 58.2%;
n = 139; UK: n = 86, ANZ: n = 53) practised at university
or teaching hospitals than at district general or commu-
nity hospitals whilst 3 respondents did not specify the
hospital type (overall 40.6%; n = 97; UK: n = 88, ANZ:
n = 9). The ICUs in these hospitals had a median (IQR)
16 (13) [UK= 15 (11) and ANZ 18 (12)] critical care
beds admitting a median (IQR) 900 (870) [UK= 750
(700) and ANZ= 1225(1100)] patients annually. The
management policy for treating patients was described
as closed by 78.2% (overall n = 187; UK: n = 133, ANZ:
n = 54) and as hybrid by 21% (overall n = 50; UK: n =42,
ANZ: n = 8) of respondents. The case-mix of patients
was described as ‘predominantly medical’ by 12.2%’, and
‘predominantly surgical’ by 11% and as ‘mixed medical
and surgical’ by 71.3% (overall n = 169; UK: n = 124 &
ANZ: n = 45) of the respondents,
Current statin prescription practices in critical care setting
The most frequently prescribed statins were simvastatin
(overall 65.2%; UK= 77.6% vs. ANZ=28.8%; p < 0.001)
and atorvastatin (overall 28.3%; UK= 15.5% vs. ANZ=
66.1%; p < 0.001). The most common reason cited for
choosing a particular statin from both the UK and ANZ
physicians was prior use (overall 56.1%; UK 54.9% vs.
ANZ 60.0%; p = 0.423). Other reported reasons included
availability from hospital pharmacy (23.6%), drug policy
(6.3%) and cost (9.9%). There was no statistically signifi-
cant difference when comparing responses from UK and
ANZ (p = 0.682). Overall, nearly half of respondents
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effects of statins (i.e. increase in hepatic transaminases,
elevated creatine kinase, rhabdomyolysis) are low when
prescribed in critically ill patients (UK 48.6% vs. ANZ
50.0%). There was no statistically significant difference
between UK and ANZ physicians’ opinions on statin
safety (p = 0.291).
Initiating new statin prescription following critical care
admission
Overall 34.3% of all respondents stated they would start
a new statin prescription for a new cardiac indication
during a patient’s ICU admission (35.6% UK vs. 30.7%
ANZ; p = 0.26). Respondents reported rarely starting a
new statin prescriptions to prevent organ dysfunction in
sepsis or to treat organ dysfunction in severe sepsis
(overall 2.5%; 1.1% UK vs. 6.4% ANZ; p = 0.03) and over-
all 0.8%; 0.6% UK vs. 1.6% ANZ; p = 0.75 respectively)
[Figure 1].
Continuing pre admission statin prescriptions following
critical care admission
Most respondents stated they would continue preadmis-
sion statin prescription for outpatient indications even if
there were no new cardiac indications in the current
ICU admission(overall 77.4%; 83.6% UK vs. 59.7% ANZ;
p < 0.001). Similarly, most respondents reported that
they would continue pre admission statin prescriptions
if there was a new cardiac indication in the current ad-
mission (overall 85.8%; 87.0% UK vs. 82.3%ANZ;
p = 0.18). However, fewer respondents would continue
pre admission statin prescriptions for preventing organ
dysfunction in sepsis or for treating organ dysfunction in
severe sepsis (overall 32.2%; 31.6% UK vs. 33.9% ANZ;
p = 0.87 and overall 31.8%; 32.8% UK vs. 29.3% ANZ;
p = 0.72 respectively) [Figure 2].Figure 1 New statin prescription practice following critical care admisStatin interventional trial
Hypothesis and trial participation
Overall, most respondents stated that they ‘neither agree
or disagree’ that statin therapy can prevent the onset of
acute organ failure in critically ill patients (overall 81.2%;
UK 80.8 vs. 82.3% ANZ; p = 0.11). Importantly, most
respondents either agreed or strongly agreed that there
is a need for a randomised clinical trial to test the hy-
pothesis that statin therapy prevents acute organ failure
in critical illness (overall 84.5%; UK 84.2% vs. ANZ
85.5%; p = 0.56). The majority of UK physicians (75.1%)
indicated a willingness to participate in a therapeutic
trial evaluating the effect of statins for preventing organ
failure in critical illness. Although in contrast no ANZ
physicians were willing at this stage to participate in the
proposed study, the vast majority were undecided (over-
all 36.0%; 17.5% UK vs. 88.7% ANZ; p < 0.001). Overall,
few were unwilling to participate in the proposed trial
(8.4%; 7.3% UK vs. 11.3% ANZ).
Type of statin therapy and safety triggers
The preferred statins for a future interventional trial
were simvastatin and atorvastatin (overall 31.9% and
29.8% respectively). Comparing the responses from phy-
sicians in the UK and ANZ, there were significant differ-
ences in the choice of statins for the proposed trial
(simvastatin - 38.4% UK vs. 13.1% ANZ; p < 0.001 and
atorvastatin - 21.5% UK vs. 54.1% ANZ; p < 0.001). Al-
most one-third (32.4%) of respondents did not report
preference to a particular statin.
We ascertained respondents’ views regarding the bio-
chemical cut offs (i.e. an increase above the upper limit
of normal in hepatic transaminases, creatine kinase and/
or bilirubin) below which they considered it safe to enrol
patients in the proposed trial. Comparing the responses
from physicians in the UK and ANZ, there weresion.
Figure 2 Continuing statin prescription practice following critical care admission.
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offs for trial enrolment with higher biochemical cut-offs
tolerated by physicians from ANZ (Table 1). Using
three-times upper limit of normal as an example to
demonstrate the heterogeneity in the choice of cut offs
we observed for: 1) transaminase levels - overall 80.7%;
UK=83.5% vs. ANZ=74.2%; p = 0.007; 2) serum creatine
kinase levels – overall 79.2%; UK= 82.8% vs. ANZ=
71.0%; p < 0.001); and 3) serum total bilirubin levels –
overall 82.6%; UK= 86.2% vs. ANZ=74.2%; p = 0.003).
Trial end points
The majority of respondents (56.5%) preferred rates of
new organ failure as the most appropriate primary out-
come of choice for power calculations and there were no
statistically significant differences when comparing
responses between UK and ANZ (60.7% UK vs. 46.8%
ANZ; p = 0.06). However, 40.6% of respondents felt that
mortality was the most appropriate primary outcome of
choice for power calculations and there were statistically
significant differences when comparing responses be-
tween UK and ANZ (35.2% UK vs. 53.2% ANZ; p = 0.02).
There were statistically significant differences in theTable 1 Cut offs for biochemical tests below which the respon
THRESHOLD OVERALL (%) UK (%
ALT/AST CK BILIRUBIN ALT/
ULN 27.6 34.7 33.9 31.6
3 ULN 42.3 33.9 37.7 36.7
5 ULN 13.8 13.4 12.1 11.3
10 ULN 2.5 2.9 1.7 2.3
>10 ULN 0.4 1.7 1.3 0
MISSING/NO RESPONSE 13.4 13.4 13.4 18.1
TOTAL 100 100 100 100
Shows the biochemical cut offs for hepatic transaminases (ALT/AST), creatine kinase
consider enrolling patients in the proposed statin interventional trial. Data are pres
p < 0.001 for CK; p = 0.003 for Bilirubin (p-values when comparing the overall frequechoice of follow up duration between the UK and ANZ
(e.g. for 28 day follow up – overall 33.3%; UK= 37.9% vs.
ANZ=22.6%; p = 0.032) [Table 2].Discussion
Key findings
We surveyed critical care physicians from a broad sam-
ple of critical care units in the UK and ANZ to obtain a
cross section of statin prescribing practices in critically
ill patients. The principal differences in reported statin
prescription practices related to decisions to continue
prior prescriptions, whether to initiate a new prescrip-
tion, and about the degree of biochemical abnormalities
physicians would tolerate when prescribing a statin. A
significantly higher proportion of UK critical care physi-
cians continued statins for outpatient indications in ICU,
whereas more ANZ critical care physicians were likely
to initiate new statin prescriptions to prevent organ dys-
function in sepsis. Interestingly, only a third of respon-
dents would initiate a statin prescription for an acute
cardiac indication in critically ill patients, whilst nearly a
third of respondents would continue a pre existing statindents would enrol patients into the proposed trial
) ANZ (%)
AST CK BILIRUBIN ALT/AST CK BILIRUBIN
41.8 38.4 16.1 14.5 21.0
26.0 32.2 58.1 56.5 53.2
10.7 8.5 21.0 21.0 22.6
2.8 1.7 3.2 3.2 1.6
0.6 1.1 1.6 4.8 1.6
18.1 18.1 0 0 0
100 100 100 100 100
(CK) and total bilirubin (bilirubin) below which the respondents would
ented as proportions. ULN= upper limit of normal. p = 0.007 for ALT/AST;
ncy distribution of the responses for ANZ and UK).
Table 2 Preferred follow up duration for the proposed
statin interventional trial
follow up duration overall - % uk - % anz - % p*
1-7 days 1.9 1.4 3.2 0.585
8-14 days 3.4 4.1 1.6 0.677
15-21 days 2.4 2.8 1.6 1.000
21-28 days 33.3 37.9 22.6 0.032
3 months 29.0 22.8 43.6 0.003
6 months 26.1 28.3 21.0 0.304
other 3.9 2.8 6.5 0.244
total 100 100 100
Shows respondents’ preferred follow up duration for the proposed statin
interventional trial. Data are presented as proportions. * p value for
comparison of United Kingdom versus Australia and p = 0.024 when
comparing the overall frequency distribution of the responses for ANZ and UK.
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secondary to sepsis syndromes.
Critical care physicians in both ANZ and UK agreed
that a randomized controlled trial is needed to test the
efficacy of statins for preventing organ dysfunction in
early critical illness. However, while the majority of UK
physicians would be willing to participate in such a trial,
the majority of ANZ physicians were undecided based
on the description of the trial that was provided. We can
only speculate on the reasons for these differences, but
one possibility is that ANZ physicians are more accus-
tomed to focusing on large-scale pragmatic trials that
aim to improve survival [33-35]. Indeed, more ANZ sur-
vey respondents wanted the interventional trial to be
powered for mortality as the primary outcome, whereas
more UK respondents preferred organ failure. The pre-
ferred statin for such an interventional trial was simvas-
tatin in the UK and atorvastatin in ANZ, possible
reflecting different prescribing practices between the two
jurisdictions. Higher biomarker thresholds for stopping
and initiating statin therapy were also reported by physi-
cians in ANZ compared to those in the UK. These im-
portant differences must be considered when designing
interventional trials of statin therapy in critical illness.
Strengths and weaknesses
The survey objectives were to evaluate opinions on
an active area of critical care research in critical ill-
ness, i.e. the potential role of statins to attenuate or
prevent organ dysfunction through the modulation of
inflammation. This survey provides important infor-
mation on the ICU community’s views on this topic.
The methodological rigour in the design of this sur-
vey, including careful sensibility testing and pilot test-
ing, should reduce the potential for bias, a common
problem in survey research [36]. We also targeted
physicians in two large international regions to ensurewe had broad representation from the critical care
community and to improve generalisability.
Our study has several limitations that are common to
most surveys. First, as with most self-administered sur-
veys, our response rate was incomplete. Although, we
used the official mailing lists there are no data on com-
pleteness and accuracy of mailing lists. Furthermore,
these mailing lists include non physician health care staff
and trainee doctors who were not our target population.
Although these groups were actively excluded the total
number at any one time is variable. However, the survey
responses represent replies from 74.6% of UK adult gen-
eral critical units and 37.1% of ANZ critical care units.
Second, our results reflect the reported practice of
respondents, and may not reflect actual practice. Third,
we are unable to rule out response bias, and some of the
non-responding physicians may have provided different
responses to survey questions.
Conclusions
Significant variability exists in the reported statin pre-
scription practices in decisions to continue prior pre-
scriptions, to initiate a new prescription, and in the
degree of biochemical abnormalities physicians would
tolerate when prescribing a statin. Our results, reflecting
the opinions of critical care physicians across UK and
ANZ, confirm that equipoise exists around the utility of
statins to prevent and/or treat organ dysfunction in the
critically ill patient population. Critical care physicians
from both regions agreed that a clinical trial is needed to
clarify the role of statins in this patient population.
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